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Summary. Inhibitor development continues to be a
major problem in the treatment of haemophilia.
Immune tolerance induction (ITI) continues to be the
most effective approach to managing this complication.
This study reviews the practice and outcome of ITI at a
single centre over a 17-year period. All 31 inhibitor
patients have haemophilia A. Two patients with hae-
mophilia A underwent two trials of ITI and a third
patient underwent three trials of ITI for a total of 35
courses of ITI in these 31 patients. Most patients had
high responding inhibitors, 22 of 31. Seventy-one
percent of haemophilia patients achieved tolerance.
Courses of ITI in African American (AA) patients with
haemophilia A were much less likely to achieve toler-
ance compared with non-AAs, 57.9% and 92%
(P = 0.04) respectively. Most trials of ITI were carried
out with recombinant products (25 of 35). While ITI
continues to be an effective therapy for patients with
inhibitors, it is less effective in AA patients, and patients
with higher inhibitor titres. In this refractory group of
patients, new approaches are needed.
Keywords: ethnic differences, factor IX, factor VIII, hae-
mophilia A, immune tolerance, inhibitor
Introduction
Approximately 30% of haemophilia A patients develop
inhibitor antibodies to replacement clotting factors
[1,2], rendering first line therapies ineffective and
requiring the administration of less effective and more
costly bypassing agents [3]. Immune tolerance induction
(ITI) was first described in the 1970s by professor H.H.
Brackmann of Bonn, Germany, involves administration
of frequent large doses of factor VIII (FVIII) products
along with activated prothrombin complexes (APC) on
a regular basis to induce the immune system to stop
production of the inhibitor antibodies [4]. This strategy
has proven successful in the majority of patients with
haemophilia A over the past few decades and ITI with
lower dose regimens has also proven effective [5]. The
optimal agent, dose and infusion schedule for each
patient have not been determined and many controver-
sies still exist and clinical trials are ongoing to answer
these questions [6]. For a minority of patients with
haemophilia A current ITI strategies are costly, difficult
and ultimately ineffective. One study examined the role
of race in likelihood of successful immune tolerance and
was unable to show a difference but had only a small
number of African American (AA) patients [5]. This
analysis is particularly important given the higher
incidence of inhibitors in the AA haemophilia popula-
tion [7,8]. Identification of factors which identify
patients less likely to achieve tolerance prior to the
start of ITI will help identify patients who may benefit
from new approaches to ITI. We have reviewed our
centre’s experience with ITI over the past 17 years and
have identified factors which appear to imply a poorer
chance of success with ITI.
Aim
The aim of this study was to study the characteristics
(including race), treatment and outcome of patients
with haemophilia with inhibitors who have undergone
ITI at the Children’s Hospital of Michigan over the past
17 years (1992–2009).
Patients and methods
Patients
In compliance with local IRB regulations, patient charts
and laboratory databases were reviewed and salient
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data were extracted. A total of 31 boys underwent 35
courses of ITI at Children’s Hospital of Michigan
between 1992 and 2009. Patients included in the study
had inhibitor titres of >0.6 Bethesda Units (BU mL)1)
on three or more tests. A total of 26 courses were in
patients with high responding inhibitor patients
(>10 BU mL)1 prior to ITI), while nine were in patients
with low responding inhibitor titres.
Monitoring
Inhibitor assays, expressed in BU mL)1, were performed
using the Bethesda method with the Nijmegen modifi-
cation (after 1996 when low inhibitor titre was detected
by Bethesda assay) [9]. Patients underwent routine
laboratory surveillance at 3-month intervals once
treated as well as specific testing when inhibitors were
suspected or at the time of significant bleeding or
planned surgery.
Immune tolerance
Immune tolerance induction consisted of doses of FVIII
ranging from 50 units kg)1 day)1 three to four times
weekly for low-responding inhibitors. Patients with
high-responding inhibitors were treated with doses of
50 units kg)1 day)1 up to 250 units kg)1 day)1. Clot-
ting factor products were given through a central venous
catheter in 30 courses, and by peripheral venipuncture in
the other five. Eight patients were given plasma-derived
FVIII (PD-FVIII) for ITI, 25 patients were given
recombinant FVIII (rFVIII) products and two patients
were treated with both. Once ITI was initiated, inhibitor
titres and FVIII recovery were measured at 2-week
intervals. When inhibitor titres fell to <0.6 BU mL)1 on
three consecutive measures, the dose of factor product
was reduced by half. If subsequent inhibitor assays
remained negative (<0.6 BU mL)1), the dose of FVIII
was gradually reduced to 25 units kg)1 day)1 three times
weekly.
Successful ITI was defined as inhibitor titre
<0.6 BU mL)1 on three consecutive tests with plasma
FVIII recovery >66% of expected and half-life >6 h.
Failure was defined as failure to achieve success in
33 months, or the absence of 20% reduction in inhibitor
titre over a 6-month period after the initial 3 months of ITI
as defined by DiMichele [10]. Additionally, three patients
had to stop ITI because of impaired venous access in the
face of rising titre inhibitors 6–10 weeks after initiation of
treatment. Low-dose ITI regimen was defined as
50 U kg)1 3–4 timesperweekwhilehigh-dose ITI regimen
was defined as 50 U kg)1 day)1 or higher daily doses.
Statistical methods
Values were calculated using Microsoft Excel 2007 with
the @ Risk software (Palisaded corp., Ithica, NY, USA)
from palisade decision tool plug-in and consisted of
simple descriptive statistics such as mean, median,
maximum and minimum as well as univariate t-tests,
chi-squared analysis and logistic regression analysis.
Results
Race
A total of 31 boys with severe haemophilia A and FVIII
inhibitors underwent 35 courses of ITI. Of the 35 courses
of ITI in haemophilia A, eight courses were in caucasian
patients (22.9%), 23 in AA (65.7%) and four in Middle
Eastern patients (11.4%). Of the 31 completed courses
of ITI, 22 patients achieved complete tolerance (71%),
nine courses failed (29%) and four patients continue on
therapy. The length of successful course of ITI was not
different between AA and non-AA patients (229.8 vs.
152.4 days, P = 0.49, t-test) (Table 1). Courses of ITI in
AAs, however, were significantly less likely to achieve
success than courses in non-AAs (57.9% vs. 92%,
P = 0.04). This difference was largely attributable to
the higher inhibitor titres at the start of ITI in AA patients
but race continued to be a predictive factor in a logistic
regression analysis including known risk factors for
unsuccessful ITI including inhibitor titre at the start of
ITI, historical peak inhibitor titre, age at diagnosis of
inhibitor and time from diagnosis of inhibitor to start of
ITI (Table 2). Using these factors, logistic regression was
able to predict success in 100% of our successful patients
and failure in 66.7% of our unsuccessful patients for an
overall 90% accuracy.
Age, exposure and time to start of ITI
The age at which patients developed an inhibitor
ranged from 2 months to 11 years 9 months (median
13 months). Patients who failed ITI had a trend
towards earlier development of inhibitor with a mean
age at development of inhibitor for those who failed
ITI of 1 year 3 months compared to 2 years 4 months
in those who were successfully tolerized (P = 0.055,
t-test). The median age at start of ITI was 4 years
8 months (range 7 months to 17 years 11 months).
Table 1. Racial differences in predictive variables for immune tolerance
induction.
African
American
Non-African
American
Historical peak (BU mL)1) 175.7 37.3
Start ITI (BU mL)1) 35.2 3.5
Peak on ITI (BU mL)1) 196.5 80.3
Time to tolerance (days) 229.8 152.4
Age at the start ITI (months) 65.2 95.9
Age at inhibitor development (months) 15.6 37.1
Exposure days prior to inhibitor 7.8 18.7
ITI, immune tolerance induction.
484 M. U. CALLAGHAN et al.
Haemophilia (2011), 17, 483–489  2010 Blackwell Publishing Ltd
The median number of exposure days prior to inhib-
itor development was 10.5 (1–47). The median time
between development of an inhibitor and initiation of
ITI was 33 months (range 0–167.1). Delay of more
than 1 year between in inhibitor development and
initiation of ITI was not associated with poorer
likelihood of success (64% <1 year, 74% >1 year,
P = 0.56 by chi-squared analysis) and time from
development of inhibitor to start of ITI did not
correlate with lower chance of successful ITI
(P = 0.44, univariate t-test).
Inhibitor titre and regimens
Nine patients had low titre inhibitors (0.6–
7.3 BU mL)1) and eight successfully completed ITI
using a low-dose ITI regimen of factor infusions 3–4
times per week of 50 U kg)1, one continues on therapy
(Table 3). A total of 22 patients with historical peak
inhibitor titres of >10 BU mL)1 (median 81 BU, range:
10.7–1280 BU mL)1) were treated with daily infusions
of 50–250 units kg)1 of FVIII products. The mean
historical peak inhibitor titres were 46.8 BU mL)1 in
the tolerized group and 296.3 BU in those who failed
ITI (P = 0.02, t-test). In only seven of the 22 successful
trials of ITI did the patient have an inhibitor titre
>50 BU mL)1 (Table 4). In the unsuccessful trials of
ITI, seven of nine had inhibitor titres >50 BU mL)1
(Table 5). Higher inhibitor titre at the start of ITI was
associated with failure; 11 trials began ITI with inhib-
itor titres in excess of 10 BU mL)1 and seven of them
failed while 15 of the 17 trials which began with
inhibitor titres below 10 BU mL)1 were successful. For
ITI, eight trials employed high-purity PD-FVIII/VWF-
containing PD products, 25 received rFVIII and two
received both. Patients were given the type of product
for ITI that they had previously received with the
exception of the patients who received both VWF-
containing PD and rFVIII. Those courses were switched
to a von Willebrand-containing PD product after initial
Table 2. Logistic regression race is a predictive factor for immune tolerance induction outcome.
Summary measures
Null deviance 36.65185812
Model deviance 20.033914
Improvement 16.61794413
P-value <0.0001
Regression coefficients Coefficient Standard error Wald value P-value Lower limit Upper limit Exp(Coef)
Constant 1.668178091 1.694270332 0.984599718 0.3248 )1.652591758 4.988947941 5.302498324
Race )0.314872272 1.367963791 )0.230175882 0.8180 )2.996081302 2.366336759 0.729882095
Inhibitor at the start of ITI )0.047770543 0.040671052 )1.174558839 0.2402 )0.127485805 0.031944718 0.953352515
Historical peak inhibitor )0.006692646 0.008693179 )0.769873286 0.4414 )0.023731277 0.010345984 0.9933297
Time to start of ITI 0.011165283 0.172683948 0.064657331 0.9484 )0.327295255 0.349625821 1.011227848
Age at inhibitor development 0.603191222 0.888816448 0.678645432 0.4974 )1.138889016 2.345271459 1.827942873
Classification matrix 1 0 Percent correct (%)
Successful 21 0 100.00
Failure 3 6 66.67
Summary classification Percent
Correct 90.00
Base 70.00
Improvement 66.67
ITI, immune tolerance induction.
Table 3. Low responder inhibitor patients who
underwent successful immune tolerance induc-
tion.
Trial
Historical
peak (BU)
Start of
ITI (BU)
Peak on
ITI (BU)
Time to
tolerance
(days)
Age
start
(months)
Time to
start
(months)
Exposure
days
prior to
inhibitor Race
15 3.1 0 0 30 33.3 21.7 4 AA
16 4.6 4.4 44 30 211.2 68.7 – ME
17 0.6 0.6 2 412 6.2 0 14 AA
18 7.1 1 1.8 104 22.4 6.6 – AA
19 1.7 0.8 0.8 29 11 0.7 10 ME
20 0.9 0.9 0.9 27 55.3 0 47 ME
21 6.5 6.5 6.5 30 – – 7 W
22 6.3 1.7 5.1 138 12 4.3 18 W
Median 3.9 1 1.9 30 22.4 4.3 12
Mean 3.9 2 2.7 100 50.2 17.7 16.7
Range 0.6–7.1 0–6.5 0–6.5 27–412 6.2–211.2 0–68.7 4–47
ITI, immune tolerance induction; W, White; AA, African American; ME, Arab American.
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poor response with rFVIII. Fourteen of 21 patients who
received only rFVIII were successfully tolerized com-
pared to seven of eight who received VWF-containing
PD products (P = 0.22, chi-squared). An analysis of the
effect of dosing regimen on chance of success or length
of ITI was not valuable in this group as there was a
considerable selection bias with low risk patients who
were very likely to respond well to ITI being treated
with lower doses of factor.
Length of ITI
In patients who became tolerized to FVIII, the average
time to achieve an inhibitor titre of <0.6 BU mL)1 was
69.5 days (14–1043 days). There was no difference in
time to tolerance between AA patients and non-AA
patients (P = 0.24, t-test). In those who did not achieve
tolerance, the mean length of the trial was 269.7 days.
Twenty-eight of the ITI trials employed a central venous
catheter and in five patients ITI was interrupted because
of recurrent infections.
Bypassing agents and prophylaxis
In 19 of the trials, the boys received FEIBA, rFVIIa or
porcine FVIII for bleeding episodes during ITI; eight of
them failed ITI and four are still on therapy. All but two
patients who successfully completed ITI went on pro-
phylaxis with FVIII. All patients who successfully
completed ITI have maintained tolerance with a mean
follow-up of 136 months (range: 6–185).
Anamnestic response
The mean rise in inhibitor titre 2–4 weeks after the start
of ITI (anamnestic response) was 37.5 BU mL)1 (stan-
dard deviation 95 BU mL)1) for those who were
successful and 166.1 for those who failed ITI, although
Table 4. High responder inhibitor patients who
underwent successful immune tolerance induc-
tion.
Trial
Historical
peak
(EU)
Start
ITI
(EU)
Peak on
ITI
(EU)
Time to
tolerance
(days)
Age
start
(months)
Time to
start
(months)
Exposure
days
prior to
inhibitor Race
1 54 3.2 95 132 58.2 11.8 14 W
2 11.2 1.5 9.2 55 79.4 24.9 4 AA
3 153 5.9 388 241 57.6 18.3 13 AA
4 34 20 20 50 19.3 13.1 14 W
5 30 11 11 45 12.7 7.3 3 AA
6 28 0 0 69 218.6 95.8 – ME
7 90 0.7 1.6 88 207 19.3 – W
8 45 6.9 224 536 138.4 12.2 – W
9 208 11 139 456 39.9 13.4 8 AA
10 57 1.7 2.3 89 152.3 73 – AA
11 160 1.8 1.9 60 202.9 12.6 – W
12 10.7 1.3 2.6 59 79.5 8.4 13 AA
13 24 22 22 49 28.7 15.4 12 AA
14 93 2.8 43 333 141 101 6 AA
Median 44.5 3 15.5 78.5 79.5 14.4 12.5
Mean 71.3 6.4 68.5 161.6 102.5 30.5 9.7
Range 10.7–208 0–22 0–388 45–536 12.7–218.6 7.3–101 1–14
ITI, immune tolerance induction; W, White; AA, African American, ME, Arab American.
Table 5. High responder inhibitor patients who
underwent unsuccessful immune tolerance
induction.
Trial
Historical
peak
(EU)
Start
ITI
(EU)
Peak
on ITI
(BU)
Duration of
trial (days)
Age start
(months)
Time to
start
(months)
Exposure
days
prior to
inhibitor Race
23 527 59 59 46 15.6 12.3 9 AA
24 16 1.6 1084 730 33.9 21.3 22 W
25 93 28 43 333 66.7 12.4 6 AA
26 18 11 43 66 16.6 13.3 6 AA
27 207 207 207 195 4.4 3.7 6 AA
28 207 7.1 147 713 124.7 120 6 AA
29 84 84 124 107 2 1.6 1 AA
30 1280 66 714 57 139.3 36.5 4 AA
31 235 94 221 180 149 123 3 AA
Median 207 62.5 177 187.5 50.3 17.3 6
Mean 296.3 62 293.6 269.7 61.4 38.2 7
Range 16–1280 1.6–207 40–1084 46–730 2–149 1.6–123 1–22
ITI, immune tolerance induction; W, White; AA, African American.
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there was considerable variability within groups and
this difference was not statistically significant (P = 0.22,
t-test).
Discussion
Risk factors for inhibitor development
It has been well established that the risk of developing
inhibitors is highest during the first few exposures to
factor products [11–13]. The median number of expo-
sure days prior to development of an inhibitor has been
consistently low in several series (9–10 exposure days).
This was true in our population with a median number
of exposure days prior to inhibitor development of 10.5.
Family history has been associated with inhibitor
development independent of the genotype. Identical
twins appear to have higher concordance of inhibitor
development than do non-twin brothers who in turn
have higher concordance than cousins [14,15]. It has
been hypothesized that this may be related to polymor-
phisms in cytokines and differences in MHC complexes
which would be more likely shared in more closely
related individuals [16]. In our study, five of the patients
had a family history of inhibitor development in
brothers or cousins.
Early reports have suggested that younger age at first
exposure to factor products lead to increased risk of
inhibitor development [17,18]. However, these differ-
ences may reflect the increased risk of early bleeds in the
same group of patients who were at high risk of
inhibitor development because of their genotype. Others
have proposed that early exposure to factor may induce
immune tolerance [19]. A small prospective study
examining the use of rFVIIa during the first 2 years of
life to avoid FVIII exposure did not seem to result in
prevention of inhibitors [20]. A more recent study of
larger cohorts has not seen a difference in inhibitor
development associated with early age at first exposure
[21]. This was also true among patients harbouring the
intron 22 inversion mutation. In our patients, the
median age at first exposure to FVIII replacement was
6 months (range: 4 days to 51 months).
Patients of African or Hispanic descent have been
found to have higher risks of inhibitor development
[8,22]. This is true even when comparing patients with
identical factor VIII mutations. It has been hypothesized
that differential distribution of polymorphisms in cyto-
kines and variations of MHC complexes may account
for this increased risk. More recently reports have
suggested that polymorphisms in FVIII itself may differ
considerably by race with six identified haplotypes. The
most commonly used recombinant factor products are
of the two haplotypes most common in caucasians.
Twenty-four percentage of AAs were found to be of F8
haplotypes not found in recombinant products, H3, H4
and H5 and patients with these haplotypes had higher
inhibitor incidence [23]. Although in patients with
mutations causing severe haemophilia very little protein
is expressed and what is expressed may not contain the
sites of these polymorphisms, it has been hypothesized
that clinically undetectable intracellular products of
these mutant genes may provide some immunomodula-
tory effect.
Risk factors for unsuccessful ITI
Our data suggest that in addition to developing inhib-
itors more frequently, AAs are less likely to respond to
ITI. In our cohort, AAs were significantly less likely to
achieve tolerance. This remained a predictive factor
even when other variables known to effect the likeli-
hood of successful ITI were accounted for a logistic
regression analysis. It is possible that genetic variables
such as cytokine polymorphisms or FVIII haplotype
differences could account for the lower success rates
seen in AAs in our study. Larger samples of inhibitor
patients will be needed to answer these questions.
Increased time from identification of an inhibitor to
the start of ITI was identified as a possible risk factor for
failure of ITI [24]. However, this was not corroborated
by other large studies [5,25]. We observed no correla-
tion between the time interval between inhibitor devel-
opment and the start of ITI and successful ITI. The
mean interval was 25.8 months in the tolerized group
and 38.2 months in those who failed ITI.
Historical peak inhibitor titre has been shown in
several studies and a large meta-analysis to correlate
with ITI failure [5,24,26,27]. An historical peak titre
>200 BU mL)1 has generally been employed as the
threshold for higher risk of failure; however, the risk
of failure appears to increase as titres increase
[25,27]. Low-responding inhibitors with peak values
<10 BU mL)1 have been reported to respond favour-
ably to ITI and often are treated with low-dose ITI
protocols with success. In our study group, the histor-
ical peak titre was an important predictor of successful
ITI. The mean historical peak inhibitor titres were
46.8 BU in the tolerized group and 296.3 BU in those
who failed ITI (P = 0.02, t-test). In only seven of the 22
successful trials of ITI did the patient have an inhibitor
titre >50 BU. In the unsuccessful trials of ITI, seven of
nine had inhibitor titres >50 BU.
In numerous studies, an inhibitor titre below
10 BU mL)1 at the start of ITI has been found to
correlate with improved outcomes [5,25,28–30]. Based
on these findings, published guidelines often suggest
delaying ITI until the inhibitor titre has fallen to
<10 BU mL)1 [31–34]. In view of the evidence that
high titres at the start of ITI increase the risk of ITI
failure, the time to start of ITI is often delayed until the
titres have fallen below 10 BU mL)1. A recent report
shows delaying the start of ITI until the inhibitor titre
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drops below 10 BU mL)1 results in a median delay of
6 months [6]. During these delays, FEIBA is to be
avoided as it contains small amounts of FVIII and may
lead to an anamnestic response in inhibitor concentra-
tion. In our study, higher inhibitor titre at the start of
ITI was associated with failure; 11 trials began ITI with
inhibitor titres in excess of 10 BU mL)1 and seven of
them failed while 15 of the 17 trials which began with
inhibitor titres below 10 BU mL)1 were successful.
In a retrospective, multicentre, multinational registry,
older age at the start of ITI was associated with worse
outcomes [24]. We did not see this effect in our study
population. The mean age of children successfully
tolerized was 83.5 months compared to 61.4 months
in those who failed ITI.
Problems with central venous access devices (CVAD)
including infection, line failure and thrombosis are
commonly result in delays and increase inhibitor titres
during ITI. These subsequently decrease the likelihood
of successful ITI. It is recommended that if possible ITI
be given through a peripheral vein. Given the frequency
of access necessary and the young age of the patients,
this is often difficult and CVADs are often required.
The dose of factor infused for ITI has varied greatly
among the published studies, ranging from 25 units kg)1
every other day to 300 units kg)1 day)1. Higher doses
have been associated with shorter time to achieve
tolerance and greater likelihood of achieving tolerance
in retrospective studies [24]. There has been considerable
debate regarding the optimal dose to achieve tolerance
safely and at reasonable cost. A randomized, controlled,
multicentre trial to test the efficacy of low- vs. high-dose
ITI in a group of patients selected as low risk based on
their historical peak titre is ongoing. In our study, low-
responding inhibitors were treated with 25 units kg)1
every other day with very good success. High-responding
inhibitors were treated with 100 units kg)1 day)1 and
doses were increased up to 250 units kg)1 day)1 in
patients who were responding poorly. Because our
treatment dose was heavily biased by the patient’s
likelihood to achieve tolerance, we are unable to evaluate
the effect of dose in our study.
von Willebrand factor-containing factor products
have recently been reported to improve the chance of
successful ITI. However, the data are limited and no
randomized trials comparing rFVIII to VWF-containing
factors head to head have been completed, although an
international study has been initiated. In our group
there was a trend towards better results with VWF-
containing PD products compared with rFVIII;
however, our sample was underpowered to detect a
difference.
For symptomatic haemorrhages in patients with high
responding inhibitor titres (whether on ITI or not),
rFVIIa and activated prothrombin complex concen-
trates (APCCs) have been the mainstay of therapy.
Given that major bleeds during ITI may compromise the
chance of successful tolerance, the use of these agents
prophylactically to avoid bleeds while on ITI as an
adjunctive therapy has been proposed, although to date
evidence comparing this strategy to on-demand use of
bypassing agents has been published [35].
There is a paucity of literature examining repeated
trials of ITI in patients who have failed trials of ITI,
although there exists a consensus that the chance of
successful tolerance in this group is low. In this study,
we have one patient who has failed ITI twice and is
currently on therapy with his third trial and has so far
had a good partial response with inhibitor titres in the
single digits. We have two additional patients who have
previously failed ITI once and are on therapy for their
second trial. One, whose recent inhibitor titres have
been <2 BU mL)1 while the other patient’s inhibitor
titre is above 100 BU.
Conclusions
Most patients with haemophilia A were able to achieve
and maintain tolerance (71%). Higher historical peak
inhibitor titres, AA race, higher inhibitor titre at the
start of ITI and early age at diagnosis of inhibitor were
the risk factors for ITI failures. Further study is needed
to recognize the patients at the highest risk of failing ITI
and to identify the best strategies for improving the
chances of successful ITI in them. Particularly in the
light of the recent discovery of haplotype differences
between ethnicities, further investigation into reasons
that AA patients have less success with ITI may not only
help this group of patients but may also offer insight
into mechanisms that lead to failure of ITI.
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